Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 1
1978 1
1979 1
1981 2
1982 3
1983 2
1986 5
1989 3
1990 1
1991 1
1992 1
1993 3
1994 3
1995 3
1996 2
1997 2
1998 3
1999 4
2000 3
2001 5
2002 6
2003 3
2004 4
2005 4
2006 2
2007 3
2008 2
2009 4
2010 7
2011 8
2012 9
2013 6
2014 7
2015 8
2016 6
2017 11
2018 10
2019 10
2020 13
2021 6
2022 5
2023 1
2024 3
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

176 results

Results by year

Filters applied: . Clear all
Page 1
Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D'Rozario J, Assouline S, Owen C, Gerecitano J, Robak T, De la Serna J, Jaeger U, Cartron G, Montillo M, Humerickhouse R, Punnoose EA, Li Y, Boyer M, Humphrey K, Mobasher M, Kater AP. Seymour JF, et al. Among authors: montillo m. N Engl J Med. 2018 Mar 22;378(12):1107-1120. doi: 10.1056/NEJMoa1713976. N Engl J Med. 2018. PMID: 29562156 Free article. Clinical Trial.
Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study.
Kater AP, Wu JQ, Kipps T, Eichhorst B, Hillmen P, D'Rozario J, Assouline S, Owen C, Robak T, de la Serna J, Jaeger U, Cartron G, Montillo M, Dubois J, Eldering E, Mellink C, Van Der Kevie-Kersemaekers AM, Kim SY, Chyla B, Punnoose E, Bolen CR, Assaf ZJ, Jiang Y, Wang J, Lefebure M, Boyer M, Humphrey K, Seymour JF. Kater AP, et al. Among authors: montillo m. J Clin Oncol. 2020 Dec 1;38(34):4042-4054. doi: 10.1200/JCO.20.00948. Epub 2020 Sep 28. J Clin Oncol. 2020. PMID: 32986498 Free PMC article. Clinical Trial.
The MURANO study: final analysis and retreatment/crossover substudy results of VenR for patients with relapsed/refractory CLL.
Kater AP, Harrup R, Kipps TJ, Eichhorst B, Owen CJ, Assouline S, Lamanna N, Robak T, de la Serna J, Jaeger U, Cartron G, Montillo M, Mellink C, Langerak AW, Chyla B, Popovic R, Jiang Y, Millen R, Lefebure M, Thadani-Mulero M, Boyer M, Seymour JF. Kater AP, et al. Among authors: montillo m. Blood. 2025 Jun 5;145(23):2733-2745. doi: 10.1182/blood.2024025525. Blood. 2025. PMID: 40009494 Free article. Clinical Trial.
Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab.
Seymour JF, Kipps TJ, Eichhorst BF, D'Rozario J, Owen CJ, Assouline S, Lamanna N, Robak T, de la Serna J, Jaeger U, Cartron G, Montillo M, Mellink C, Chyla B, Panchal A, Lu T, Wu JQ, Jiang Y, Lefebure M, Boyer M, Kater AP. Seymour JF, et al. Among authors: montillo m. Blood. 2022 Aug 25;140(8):839-850. doi: 10.1182/blood.2021015014. Blood. 2022. PMID: 35605176 Free PMC article. Clinical Trial.
Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Munir T, Brown JR, O'Brien S, Barrientos JC, Barr PM, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Kipps TJ, Moreno C, Montillo M, Burger JA, Byrd JC, Hillmen P, Dai S, Szoke A, Dean JP, Woyach JA. Munir T, et al. Among authors: montillo m. Am J Hematol. 2019 Dec;94(12):1353-1363. doi: 10.1002/ajh.25638. Epub 2019 Oct 13. Am J Hematol. 2019. PMID: 31512258 Free PMC article. Clinical Trial.
Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trial.
Tedeschi A, Frustaci AM, Condoluci A, Coscia M, Chiarle R, Zinzani PL, Motta M, Gaidano G, Quaresmini G, Scarfò L, Catania G, Deodato M, Jones R, Tabanelli V, Griggio V, Stüssi G, Calleri A, Pini K, Cairoli R, Zenz T, Signori A, Zucca E, Rossi D, Montillo M. Tedeschi A, et al. Among authors: montillo m. Lancet Oncol. 2024 Oct;25(10):1298-1309. doi: 10.1016/S1470-2045(24)00396-6. Epub 2024 Sep 10. Lancet Oncol. 2024. PMID: 39270702 Clinical Trial.
Duvelisib for the treatment of chronic lymphocytic leukemia.
Frustaci AM, Tedeschi A, Deodato M, Zamprogna G, Cairoli R, Montillo M. Frustaci AM, et al. Among authors: montillo m. Expert Opin Pharmacother. 2020 Aug;21(11):1299-1309. doi: 10.1080/14656566.2020.1751123. Epub 2020 Apr 15. Expert Opin Pharmacother. 2020. PMID: 32292084 Review.
Infectious toxicity using alemtuzumab.
Nosari A, Montillo M, Morra E. Nosari A, et al. Among authors: montillo m. Haematologica. 2004 Dec;89(12):1415-9. Haematologica. 2004. PMID: 15590388 No abstract available.
176 results